Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease
…, D Le Febvre de Nailly, F Charbonnier-Beaupel… - Cell and tissue …, 2018 - Springer
There is currently no cure for Parkinson’s disease. The symptomatic therapeutic strategy
essentially relies on dopamine replacement whose efficacy was demonstrated more than 50 …
essentially relies on dopamine replacement whose efficacy was demonstrated more than 50 …
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial
…, C Bonnet, F Charbonnier‐Beaupel… - Annals of …, 2011 - Wiley Online Library
… 12,5 = 53.3, p = 0.0002 for the effect of entacapone in the COMT HH group; F 12,4 = 10.5, p
= 0.02 for the effect of entacapone in the COMT LL group; F 1,31 = 4.5, p = 0.04 for genotype/…
= 0.02 for the effect of entacapone in the COMT LL group; F 1,31 = 4.5, p = 0.04 for genotype/…
[PDF][PDF] RAD51 haploinsufficiency causes congenital mirror movements in humans
Congenital mirror movements (CMM) are characterized by involuntary movements of one
side of the body that mirror intentional movements on the opposite side. CMM reflect …
side of the body that mirror intentional movements on the opposite side. CMM reflect …
The autophagy/lysosome pathway is impaired in SCA7 patients and SCA7 knock-in mice
…, MP Muriel, F Beaumatin, F Charbonnier-Beaupel… - Acta …, 2014 - Springer
There is still no treatment for polyglutamine disorders, but clearance of mutant proteins might
represent a potential therapeutic strategy. Autophagy, the major pathway for organelle and …
represent a potential therapeutic strategy. Autophagy, the major pathway for organelle and …
A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia
…, M Vidailhet, N Cozic, F Charbonnier-Beaupel… - Neurology, 2016 - AAN Enterprises
Objective: To evaluate the efficacy and safety of zonisamide in patients with myoclonus-dystonia.
Methods: We conducted a randomized, double-blind, placebo-controlled crossover trial …
Methods: We conducted a randomized, double-blind, placebo-controlled crossover trial …
Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease
…, K Tahiri, F Charbonnier-Beaupel… - Parkinsonism & related …, 2014 - Elsevier
… b , Stéphanie Lejeune a c , Florence Cormier-Dequaire a c , Khadija Tahiri c , Fanny
Charbonnier-Beaupel c d e , Nathalie Rouaix f , Alain Duhamel … Fanny Charbonnier-Beaupel: 1c …
Charbonnier-Beaupel c d e , Nathalie Rouaix f , Alain Duhamel … Fanny Charbonnier-Beaupel: 1c …
[HTML][HTML] Bee venom for the treatment of Parkinson disease–a randomized controlled clinical trial
…, N Abuaf, H Gaouar, S Salhi, F Charbonnier-Beaupel… - PloS one, 2016 - journals.plos.org
In the present study, we examined the potential symptomatic and/or disease-modifying effects
of monthly bee venom injections compared to placebo in moderatly affected Parkinson …
of monthly bee venom injections compared to placebo in moderatly affected Parkinson …
Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia
F Charbonnier-Beaupel, M Malerbi… - Journal of …, 2015 - Soc Neuroscience
In Parkinson's disease, long-term dopamine replacement therapy is complicated by the
appearance of l-DOPA-induced dyskinesia (LID). One major hypothesis is that LID results from …
appearance of l-DOPA-induced dyskinesia (LID). One major hypothesis is that LID results from …
A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing–remitting multiple sclerosis
…, E Maillart, A Ungureanu, F Charbonnier-Beaupel… - Journal of …, 2023 - Springer
Background Multiple sclerosis (MS) is associated with regulatory T cells (Tregs) insufficiency
while low-dose interleukin-2 (IL2 LD ) activates Tregs and reduces disease activity in …
while low-dose interleukin-2 (IL2 LD ) activates Tregs and reduces disease activity in …
Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease
…, M Vidailhet, F Charbonnier‐Beaupel… - Movement …, 2018 - Wiley Online Library
Background Impulse control disorders are frequently associated with dopaminergic therapy
in Parkinson's disease. Genetic studies have suggested a high heritability of impulse control …
in Parkinson's disease. Genetic studies have suggested a high heritability of impulse control …